We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J’s RSV Vaccine Reduced Disease Risk by 80 Percent in Older Adults
J&J’s RSV Vaccine Reduced Disease Risk by 80 Percent in Older Adults
Johnson and Johnson’s investigational vaccine against respiratory syncytial virus (RSV) reduced the risk of RSV-associated lower respiratory tract disease by 80 percent in older adults in a phase 2b trial.